|
Volumn 21, Issue 16, 2015, Pages s331-s340
|
The economic implications of biosimilars
a a |
Author keywords
[No Author keywords available]
|
Indexed keywords
BIOSIMILAR AGENT;
COST CONTROL;
DRUG APPROVAL;
DRUG COST;
ECONOMIC ASPECT;
ECONOMICS;
HEALTH CARE COST;
HUMAN;
REIMBURSEMENT;
UNITED STATES;
BIOSIMILAR PHARMACEUTICALS;
COST SAVINGS;
DRUG APPROVAL;
DRUG COSTS;
ECONOMIC COMPETITION;
HEALTH EXPENDITURES;
HUMANS;
REIMBURSEMENT MECHANISMS;
UNITED STATES;
|
EID: 85012855515
PISSN: None
EISSN: 19362692
Source Type: Journal
DOI: None Document Type: Article |
Times cited : (50)
|
References (0)
|